141 related articles for article (PubMed ID: 16719542)
1. Predicting the toxicity of weekly docetaxel in advanced cancer.
Charles KA; Rivory LP; Stockler MR; Beale P; Beith J; Boyer M; Clarke SJ
Clin Pharmacokinet; 2006; 45(6):611-22. PubMed ID: 16719542
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
3. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
ten Tije AJ; Verweij J; Carducci MA; Graveland W; Rogers T; Pronk T; Verbruggen MP; Dawkins F; Baker SD
J Clin Oncol; 2005 Feb; 23(6):1070-7. PubMed ID: 15718305
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting docetaxel-related toxicity: experience at a single institution.
Massacesi C; Marcucci F; Rocchi MB; Mazzanti P; Pilone A; Bonsignori M
J Chemother; 2004 Feb; 16(1):86-93. PubMed ID: 15078005
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
10. Practical aspects of weekly docetaxel administration schedules.
Hainsworth JD
Oncologist; 2004; 9(5):538-45. PubMed ID: 15477638
[TBL] [Abstract][Full Text] [Related]
11. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.
Harvey V; Mouridsen H; Semiglazov V; Jakobsen E; Voznyi E; Robinson BA; Groult V; Murawsky M; Cold S
J Clin Oncol; 2006 Nov; 24(31):4963-70. PubMed ID: 17033039
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
[TBL] [Abstract][Full Text] [Related]
14. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Baker SD; Zhao M; Lee CK; Verweij J; Zabelina Y; Brahmer JR; Wolff AC; Sparreboom A; Carducci MA
Clin Cancer Res; 2004 Mar; 10(6):1976-83. PubMed ID: 15041715
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
